Ionis Reports Two-Year P-II OLE Study Results of Donidalorsen for the Treatment of Hereditary Angioedema
- The company highlighted the results from the 2yr. P-II OLE study evaluating donidalorsen which resulted in consistent efficacy & safety with an overall sustained mean reduction in HAE attack rates from baseline through 2yrs. across dosing groups
- In the P-II study, donidalorsen (80mg, qm) showed a 90% reduction in angioedema attacks over PBO after 1st dose through 17wk., 97% reduction in angioedema attacks starting with 2nd dose, improvement in QoL. The therapy continues to show a favorable safety & tolerability profile with added 2yr. OLE data
- The patient enrollment has been completed in the P-III study (OASIS-HAE) evaluating donidalorsen for angioedema attacks. The results are expected in H1’24
Ref: PRNewswire | Image: Ionis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.